Literature DB >> 24421490

ISMP Adverse Drug Reactions.

.   

Abstract

The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Administration's (FDA's) MedWatch program (800-FDA-1088). If you have reported an interesting, preventable ADR to MedWatch, please consider sharing the account with our readers. Write to Dr. Mancano at ISMP, 200 Lakeside Drive, Suite 200, Horsham, PA 19044 (phone: 215-707-4936; e-mail: mmancano@temple.edu). Your report will be published anonymously unless otherwise requested. This feature is provided by the Institute for Safe Medication Practices (ISMP) in cooperation with the FDA's MedWatch program and Temple University School of Pharmacy. ISMP is an FDA MedWatch partner.

Year:  2013        PMID: 24421490      PMCID: PMC3839462          DOI: 10.1310/hpj4805-360

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  5 in total

1.  Neuroleptic malignant syndrome associated with risperidone long-acting injection: a case report.

Authors:  Toru Yamashita; Yasuo Fujii; Fuminari Misawa
Journal:  J Clin Psychopharmacol       Date:  2013-02       Impact factor: 3.153

2.  A case of high-dose venlafaxine-related psychosis.

Authors:  Evelyn A Dennison; B Mahendri Raidoo; Robyn Cruz; Deshandra Raidoo
Journal:  J Clin Psychopharmacol       Date:  2013-02       Impact factor: 3.153

3.  Telaprevir-related dermatitis.

Authors:  Jean-Claude Roujeau; Maja Mockenhaupt; Steven R Tahan; Joshua Henshaw; Emily C Martin; Matt Harding; Ben van Baelen; Leif Bengtsson; Priya Singhal; Robert S Kauffman; Robert S Stern
Journal:  JAMA Dermatol       Date:  2013-02       Impact factor: 10.282

Review 4.  Tigecycline-related pancreatitis: a review of spontaneous adverse event reports.

Authors:  Emmanuel Okon; Christian Engell; Robbert van Manen; Jack Brown
Journal:  Pharmacotherapy       Date:  2013-01       Impact factor: 4.705

5.  Neurologic adverse effects of ranolazine in an elderly patient with renal impairment.

Authors:  Robert A Southard; Rachel M Blum; An H Bui; Ron Blankstein
Journal:  Pharmacotherapy       Date:  2013-01       Impact factor: 4.705

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.